Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the company's Consulting Medical Officer and founder of the Hunter-Hopkins Center. The segment focuses on the results from AIM's Phase 2 study of Ampligen® for Post-COVID fatigue condition (AMP-518). Dr. Lapp, a Key Opinion Leader with over 25 years of experience treating Chronic Fatigue Syndrome and Fibromyalgia, discusses the study's findings regarding efficacy and safety.
ISS has recommended AIM ImmunoTech shareholders vote FOR Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting.
ISS found the Activist Group's plan , with only one nominee having relevant life sciences expertise, and highlighted concerns about nominee Robert L. Chioini's track record and connections to securities law felons, recommending against his and nominee Todd A. Deutsch's election.
AIM highlighted a $15 million+ investment partnership between activist nominees Ted Kellner and Paul Sweeney, questioning their independence. The Company urged shareholders to vote for all four incumbent candidates on the WHITE proxy card.
Dr. William M. Mitchell emphasized the Company's ability to secure funding for clinical trials and the expertise of the Board members, particularly Tom Equels and Stewart Appelrouth. AIM remains focused on high-value indications like pancreatic cancer to create long-term value.
AIM ImmunoTech has issued a presentation urging shareholders to vote against four director candidates nominated by an activist investor group at the upcoming 2024 Annual Meeting. The company highlights serious concerns about the nominees: Robert Chioini was previously fired for mismanagement, Todd Deutsch has connections to individuals involved in securities fraud, Ted Kellner was found by court to have provided false information to shareholders, and Paul Sweeney lacks independence due to extensive business ties with Kellner.
The activist group is seeking over $5 million in reimbursement for failed litigation expenses, plus additional proxy contest costs, without shareholder approval.
AIM ImmunoTech has issued a statement refuting claims made by an activist investor group regarding their attempt to take control of the company's Board of Directors at the upcoming 2024 Annual Meeting. The company specifically addresses the activist group's false claim about AIM's historical share price, stating that contrary to the group's assertion of $87.15 on February 25, 2016, the stock was actually trading at $0.16 as of March 15, 2016.
The Delaware Court of Chancery has previously found that the activist group made multiple misleading statements and omissions in their 2022 and 2023 nomination notices. The company urges shareholders to vote 'FOR' all four incumbent Board candidates.
AIM ImmunoTech has announced a cash conservation plan to maintain momentum in achieving clinical milestones. Independent directors will receive 100% of their compensation in company stock instead of cash. Previously disclosed amendments to executive employment agreements reduce cash salaries by $200,000 for CEO Thomas Equels and $50,000 for COO Peter Rodino, replacing these amounts with stock compensation. Notably, CEO Equels purchased 361,458 company shares between November 2023 and November 2024. The Board emphasizes its belief in Ampligen's potential to address unmet medical needs and create shareholder value through commercialization.
AIM ImmunoTech (NYSE American: AIM) has issued a presentation defending its current board members ahead of its 2024 Annual Meeting. The company highlights its clinical development progress, particularly in pancreatic cancer, and ongoing partnerships with AstraZeneca and Merck. The presentation warns against an Activist Group seeking board control, noting their demand for over $5 million in reimbursement for previous litigation costs. The company reveals that despite settlement attempts, the Activist Group demanded up to $8 million, representing over 50% of AIM's market cap. The board urges shareholders to vote for incumbent candidates and reject the Activist Group's proposals.
The Kellner Group, AIM Immunotech's largest stockholder, urges shareholders to vote using the GOLD proxy card to elect new board members, citing serious concerns about the incumbent board's conduct. The Delaware Supreme Court ruled that the board breached its fiduciary duties by adopting inequitable bylaws to maintain control. The group estimates the board spent $15-20 million in litigation to prevent meaningful director elections, contributing to a 99+% stock price decline. The Kellner Group nominees - Ted Kellner, Todd Deutsch, Robert Chioini, and Paul Sweeney - promise to bring needed change to address increasing losses, excessive spending, and poor governance.
AIM ImmunoTech announced the publication of data from Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating Ampligen® as part of a chemokine-modulating regimen in early-stage triple-negative breast cancer (TNBC). The study results, published in The Journal for ImmunoTherapy of Cancer, showed that the Ampligen-containing regimen can modify the tumor microenvironment and release cytokines that attract killer T-cells into early-stage TNBC tumors. Study principal investigator Dr. Shipra Gandhi noted the promising results while emphasizing the need for validation in a larger study.
AIM ImmunoTech (NYSE American: AIM) reported its Q3 2024 financial results, highlighting progress in Ampligen® clinical development programs, particularly in pancreatic cancer treatment. The company reported cash and equivalents of $7.2 million, with reduced quarterly losses of $3.7 million ($0.06 per share) compared to $7.8 million ($0.16 per share) in Q3 2023. R&D expenses decreased to $1.4 million from $2.7 million, while G&A expenses reduced to $3.1 million from $5.4 million year-over-year. Key developments include positive preliminary data in pancreatic cancer studies, progress in Long-COVID research, and a new U.S. patent for Ampligen in endometriosis treatment.
The Kellner Group, AIM Immunotech's largest stockholder, is urging shareholders to vote for board changes using the gold proxy card. The Delaware Supreme Court ruled that the incumbent board breached fiduciary duties by adopting bylaws in 2023 to interfere with Kellner's nomination notice. The group estimates the board spent $15-20 million in the past two years fighting stockholder efforts for change. Under current leadership, AIM's stock price has declined over 99%, and its financial condition has deteriorated significantly. The Kellner Group nominees - Ted Kellner, Todd Deutsch, Robert L. Chioini, and Paul Sweeney - promise to bring new skills and experience to improve company performance.
